

**Selected Startups**  
**for Support in Participation at BIO International 2025**  
**and Pitch at the LINK-J Japan Night @Boston**

---

**Biomy Inc.**     <https://www.biomy-tech.com/>

**[Overview]**

Biomy, Inc. is a Japanese company that has developed DeepPathFinder™, a unique AI/DL-automated digital pathology algorithm that can detect, identify, and quantify immune cells in tumor and tumor micro-environment tissues from H&E only (short demo movie:

<https://www.youtube.com/watch?v=SsQZy9QKiuY>).

Furthermore, DeepPathFinder™ is equipped with Spatial Biology features and delivers tremendous value for Precision Medicine (e.g., diagnosis, patient stratification, evaluation of treatment response, prognosis) as well as for the discovery of novel Pathological Biomarkers in multiple therapeutic areas such as Immuno-Oncology, and Auto-Immune and Inflammatory Diseases.

**[Who we would like to match with / What support we need]**

Biomy is actively seeking partnerships and R&D collaborations based on applying its DeepPathFinder™ digital pathology platform to Immuno-Oncology, and Auto-Immune and Inflammatory Diseases. Discover more about our latest research and explore potential collaborations that are setting new standards in Precision and Personalized Medicine!

---

**Crafton Biotechnology Co., Ltd.**     <https://craftonbio.com/en/>

**[Overview]**

Crafton Biotechnology is an mRNA biotech focusing on developing novel mRNA therapeutics for oncology and rare disease. Crafton has a novel mRNA platform technology (PureCap®) that allows for ultra-pure mRNA molecules that are highly safe and efficacious.

**[Who we would like to match with / What support we need]**

We are looking for pharma and biotechs interested in our novel mRNA platform technology for co-development as well as early stage investors looking for the next breakthrough technology in this emerging modality.

---

**iXgene Inc.**     <https://www.ixgene.inc/en/>

**[Overview]**

iXgene Inc. is a Japanese biotech company developing allogeneic iPS cell-derived therapies for hard-to-treat cancers. Our lead program, IXG-001, targets recurrent glioblastoma through localized activation of a potent anti-cancer prodrug. The program is currently in preclinical development, with a Phase 1 clinical trial in Japan expected to begin in 2026.

**[Who we would like to match with / What support we need]**

We are seeking global partners to

- (1) build a strong clinical and manufacturing network in preparation for our global Phase 2 trial in 2027
  - (2) explore co-development and licensing opportunities for our technology with biopharma companies
  - (3) engage with global venture investors in preparation for our upcoming Series B/C fundraising.
- 

**Kyoto Drug Discovery & Development Co., Ltd.**

<https://www.kyoto-drug.com/en/>

**[Overview]**

Kyoto Drug Discovery & Development is a biopharmaceutical company founded in 2015 as a spin-out from Kyoto University. Our compound, KUS121, preserves ATP for vital functions and suppresses cell death. It has entirely new pharmacological effects that were previously unavailable. KUS121 is particularly effective in treating ischemic diseases, degenerative diseases, and inflammatory diseases. We are currently conducting Phase 2 clinical trials in the United States for the orphan disease, central retinal artery occlusion (CRAO).

**[Who we would like to match with / What support we need]**

We are currently planning international Phase 3 clinical trials in Japan and the United States and are seeking investors for funding, as well as pharmaceutical companies to collaborate on development.

---

**MiRNDa, Inc.**

**[Overview]**

A startup company aiming to realize a world where cancer can be cured through the social implementation of cancer screening based on our proprietary RNA modification technology. We are advancing product and business development toward the social implementation of screening services for cancers with high unmet medical needs in daily clinical practices, starting with pancreatic cancer, that has a particularly low 5-year survival rate.

**[Who we would like to match with / What support we need]**

1. We are seeking to be matched with venture capital firms that may be interested in investing in us. As we are prioritizing the launch in the United States, we really would like to engage with U.S.-based venture capital firms.
2. As part of our search for potential collaboration/alliance partners (with the possibility of considering CVC opportunities as well), we are seeking to be matched with pharmaceutical companies that have oncology-related products, as well as with organizations such as U.S.-based health insurance providers (e.g. UnitedHealthcare) and companies offering clinical testing and diagnostic services with CLIA Lab (e.g. LabCorp).

---

\*In alphabetical order